QianJin Pharmaceutical(SH:600479) 智通财经网·2026-02-09 09:31Core Viewpoint - Qianjin Pharmaceutical (600479.SH) reported a total operating revenue of 3.635 billion yuan for the fiscal year 2025, reflecting a year-on-year growth of 0.13%, while the net profit attributable to shareholders increased by 24.74% to 288 million yuan [1] Group 1: Financial Performance - The total operating revenue for 2025 was 3.635 billion yuan, showing a slight increase of 0.13% compared to the previous year [1] - The net profit attributable to shareholders reached 288 million yuan, marking a significant year-on-year growth of 24.74% [1] Group 2: Growth Drivers - The primary reasons for the performance growth include stable revenue growth from core industrial enterprises and improved profitability [1] - The acquisition of stakes in two subsidiaries, Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. (28.92% stake) and Hunan Qianjin Xieli Pharmaceutical Co., Ltd. (68% stake), contributed to the financial results, with these stakes being consolidated under the new ownership structure starting in October and November 2025, respectively [1]